CY1112298T1 - Ενωσεις και μεθοδοι για ρυθμιση fxr - Google Patents
Ενωσεις και μεθοδοι για ρυθμιση fxrInfo
- Publication number
- CY1112298T1 CY1112298T1 CY20121100098T CY121100098T CY1112298T1 CY 1112298 T1 CY1112298 T1 CY 1112298T1 CY 20121100098 T CY20121100098 T CY 20121100098T CY 121100098 T CY121100098 T CY 121100098T CY 1112298 T1 CY1112298 T1 CY 1112298T1
- Authority
- CY
- Cyprus
- Prior art keywords
- methods
- fxr
- setting units
- dyslipidemia
- units
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Indole Compounds (AREA)
Abstract
Ενώσεις του τύπου (Ι): τύπου (Ι) όπου οι μεταβλητές είναι όπως ορίζεται εδώ και φαρμακευτικές συνθέσεις αυτών και μέθοδοι χρήσης αυτών αποκαλύπτονται ως χρήσιμες για θεραπεία δυσλιπιδαιμίας και ασθενειών που σχετίζονται προς δυσλιπιδαιμία.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94997407P | 2007-07-16 | 2007-07-16 | |
| EP08781651A EP2178851B1 (en) | 2007-07-16 | 2008-07-11 | Compounds and methods for modulating fxr |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1112298T1 true CY1112298T1 (el) | 2015-12-09 |
Family
ID=39855171
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20121100098T CY1112298T1 (el) | 2007-07-16 | 2012-01-27 | Ενωσεις και μεθοδοι για ρυθμιση fxr |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US8153624B2 (el) |
| EP (1) | EP2178851B1 (el) |
| JP (1) | JP5373788B2 (el) |
| KR (1) | KR101157334B1 (el) |
| CN (1) | CN101743232B (el) |
| AR (1) | AR067540A1 (el) |
| AT (1) | ATE539065T1 (el) |
| AU (1) | AU2008276236B2 (el) |
| BR (1) | BRPI0814571A2 (el) |
| CA (1) | CA2693406C (el) |
| CL (1) | CL2008002051A1 (el) |
| CO (1) | CO6270212A2 (el) |
| CY (1) | CY1112298T1 (el) |
| DK (1) | DK2178851T3 (el) |
| DO (1) | DOP2010000018A (el) |
| EA (1) | EA016475B1 (el) |
| EC (1) | ECSP109879A (el) |
| ES (1) | ES2376176T3 (el) |
| HR (1) | HRP20120048T1 (el) |
| IL (1) | IL202234A0 (el) |
| MA (1) | MA31683B1 (el) |
| MX (1) | MX2010000502A (el) |
| PE (1) | PE20090809A1 (el) |
| PL (1) | PL2178851T3 (el) |
| PT (1) | PT2178851E (el) |
| RS (1) | RS52216B (el) |
| SI (1) | SI2178851T1 (el) |
| SV (1) | SV2010003458A (el) |
| TN (1) | TN2010000028A1 (el) |
| TW (1) | TW200906823A (el) |
| WO (1) | WO2009012125A1 (el) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| WO2012087520A1 (en) * | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| US20140039007A1 (en) * | 2010-12-20 | 2014-02-06 | David C. Tully | Compositions and methods for modulating farnesoid x receptors |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| CA2905242C (en) | 2013-03-15 | 2016-11-29 | Pfizer Inc. | Indole compounds that activate ampk |
| AU2014320463B2 (en) | 2013-09-11 | 2018-08-02 | Centre National De La Recherche Scientifique (Cnrs) | Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection |
| SG11201603026PA (en) * | 2013-11-05 | 2016-05-30 | Novartis Ag | Compositions and methods for modulating farnesoid x receptors |
| CN104045635A (zh) * | 2014-06-23 | 2014-09-17 | 华东理工大学 | 3,4,5-三取代异恶唑类化合物及其用途 |
| EP3006939A1 (en) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| EP3034499A1 (en) * | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| SG11201706347SA (en) | 2015-02-06 | 2017-09-28 | Intercept Pharmaceuticals Inc | Pharmaceutical compositions for combination therapy |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| SI3277286T1 (sl) | 2015-03-31 | 2021-09-30 | Enanta Pharmaceuticals, Inc. | Derivati žolčne kisline kot antagonisti FXR/TGR5 in metode za njihovo uporabo |
| JP6879931B2 (ja) | 2015-04-07 | 2021-06-02 | インターセプト ファーマシューティカルズ， インコーポレイテッド | 併用療法用の医薬組成物 |
| CN106946867B (zh) * | 2016-01-06 | 2019-11-12 | 广州市恒诺康医药科技有限公司 | Fxr受体调节剂及其制备方法和用途 |
| CN107021958A (zh) * | 2016-02-01 | 2017-08-08 | 山东轩竹医药科技有限公司 | Fxr受体激动剂 |
| BR112018069789A2 (pt) | 2016-03-28 | 2019-01-29 | Intercept Pharmaceuticals Inc | medicamento obtido pela combinação do agonista de fxr e arb |
| US10080742B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017201152A1 (en) | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10149835B2 (en) | 2016-05-18 | 2018-12-11 | Elmore Patent Law Group, P.C. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| US10144729B2 (en) | 2016-05-18 | 2018-12-04 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| AR108710A1 (es) | 2016-06-13 | 2018-09-19 | Gilead Sciences Inc | Compuestos modulares de fxr (nr1h4) |
| CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| WO2018039384A1 (en) | 2016-08-23 | 2018-03-01 | Ardelyx, Inc. | Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as fxr activators |
| MA55632A (fr) * | 2016-08-23 | 2022-02-16 | Ardelyx Inc | Procédé de preparation de modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques |
| AU2017328135B2 (en) * | 2016-09-14 | 2020-04-30 | Novartis Ag | Novel regimes of FXR agonists |
| KR20190056436A (ko) | 2016-10-04 | 2019-05-24 | 이난타 파마슈티칼스, 인코포레이티드 | Fxr 작용제로서의 이속사졸 유사체 및 그의 사용 방법 |
| US10597391B2 (en) | 2016-10-26 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof |
| CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| CN108218852A (zh) * | 2016-12-15 | 2018-06-29 | 宁波百纳西药业有限公司 | 一种螺环化合物、其制备方法、组合物及用途 |
| PL4122464T3 (pl) | 2017-03-28 | 2024-09-16 | Gilead Sciences, Inc. | Kombinacje terapeutyczne do leczenia chorób wątroby |
| WO2018178260A1 (en) | 2017-03-30 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
| KR102168543B1 (ko) * | 2017-04-12 | 2020-10-21 | 일동제약(주) | 핵 수용체의 효능제인 아이속사졸 유도체 및 이의 용도 |
| CN109265471B (zh) * | 2017-06-30 | 2021-06-04 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
| CN109320509B (zh) * | 2017-07-31 | 2022-02-08 | 轩竹生物科技股份有限公司 | Fxr受体激动剂 |
| JP7271513B2 (ja) | 2017-09-14 | 2023-05-11 | アルデリックス， インコーポレイテッド | 代謝関連の突然変異誘発性及び線維性の症状及び障害を治療するためのホルモン受容体調節薬 |
| KR20200083529A (ko) | 2017-11-01 | 2020-07-08 | 브리스톨-마이어스 스큅 컴퍼니 | 파르네소이드 x 수용체 조정제로서의 알켄 스피로시클릭 화합물 |
| ES2944601T3 (es) | 2017-11-01 | 2023-06-22 | Bristol Myers Squibb Co | Compuestos multicíclicos como moduladores del receptor farnesoide X |
| SG11202003825TA (en) | 2017-11-01 | 2020-05-28 | Bristol Myers Squibb Co | Spirocyclic compounds as farnesoid x receptor modulators |
| EP3704113B1 (en) | 2017-11-01 | 2023-10-11 | Bristol-Myers Squibb Company | Bridged bicyclic compounds as farnesoid x receptor modulators |
| EP3704106B1 (en) * | 2017-11-01 | 2023-04-12 | Bristol-Myers Squibb Company | Alkene compounds as farnesoid x receptor modulators |
| WO2019118571A1 (en) | 2017-12-12 | 2019-06-20 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| US11667629B2 (en) * | 2017-12-22 | 2023-06-06 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Isoxazole derivative, preparation method therefor, and use thereof |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| WO2019160813A1 (en) | 2018-02-14 | 2019-08-22 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| CN110452235B (zh) * | 2018-05-08 | 2023-02-17 | 中国科学院上海药物研究所 | 一类含氟异噁唑类化合物及其制备方法、药物组合物和用途 |
| SG11202101863YA (en) * | 2018-08-30 | 2021-03-30 | Terns Pharmaceuticals Inc | Treating liver disorders |
| DK3911647T3 (da) | 2019-01-15 | 2024-02-26 | Gilead Sciences Inc | Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan |
| WO2020168152A2 (en) | 2019-02-15 | 2020-08-20 | Bristol-Myers Squibb Company | Substituted amide compounds useful as farnesoid x receptor modulators |
| AR118050A1 (es) | 2019-02-15 | 2021-09-15 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos como moduladores del receptor farnesoide x |
| JP2022519906A (ja) | 2019-02-19 | 2022-03-25 | ギリアード サイエンシーズ， インコーポレイテッド | Ｆｘｒアゴニストの固体形態 |
| US11555032B2 (en) | 2019-05-13 | 2023-01-17 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| JP2022536060A (ja) | 2019-05-30 | 2022-08-12 | インターセプト ファーマシューティカルズ， インコーポレイテッド | 胆汁鬱滞性肝疾患の処置で使用するためのｆｘｒアゴニストおよびフィブラートを含む医薬組成物 |
| CA3139291A1 (en) | 2019-07-18 | 2021-01-21 | Jacky Vonderscher | Method for decreasing adverse-effects of interferon |
| WO2021092474A1 (en) * | 2019-11-08 | 2021-05-14 | Terns, Inc. | Treating liver disorders |
| WO2021144330A1 (en) | 2020-01-15 | 2021-07-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| IL298144A (en) * | 2020-05-13 | 2023-01-01 | Terns Pharmaceuticals Inc | Combined treatment of liver disorders |
| AU2021332217A1 (en) | 2020-08-25 | 2023-05-11 | Eli Lilly And Company | Polymorphs of an ssao inhibitor |
| IL301238A (en) * | 2020-09-11 | 2023-05-01 | Terns Pharmaceuticals Inc | Solid dispersible formulations of an FXR agonist |
| WO2022082197A1 (en) * | 2020-10-15 | 2022-04-21 | Eli Lilly And Company | Polymorphs of an fxr agonist |
| CA3204800A1 (en) | 2021-01-14 | 2022-07-21 | Raphael Darteil | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| EP4329761A1 (en) | 2021-04-28 | 2024-03-06 | ENYO Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
| CA3238082A1 (en) | 2021-11-11 | 2023-05-19 | Terns Pharmaceuticals, Inc. | Combination of a ssao inhibitor and thr-beta agonist for use in the treatment of liver disorders |
| WO2023220404A1 (en) * | 2022-05-13 | 2023-11-16 | Terns Pharmaceuticals, Inc. | Treatment of non-alcoholic steatohepatitis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH07138258A (ja) * | 1993-11-16 | 1995-05-30 | Taiho Yakuhin Kogyo Kk | チアゾリジンジオン誘導体又はその塩 |
| CA2356887A1 (en) | 1998-12-23 | 2000-06-29 | Glaxo Group Limited | Assays for ligands for nuclear receptors |
| US7105556B2 (en) * | 2001-05-30 | 2006-09-12 | Bristol-Myers Squibb Company | Conformationally constrained analogs useful as antidiabetic and antiobesity agents and method |
| US6967212B2 (en) * | 2001-05-30 | 2005-11-22 | Bristol-Myers Squibb Company | Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method |
| ATE381542T1 (de) | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| MXPA05000279A (es) | 2002-07-09 | 2005-03-31 | Squibb Bristol Myers Co | Derivados heterociclicos sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo. |
| WO2004048349A1 (en) * | 2002-11-22 | 2004-06-10 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| EP1984360B1 (en) | 2006-02-03 | 2014-01-15 | Eli Lilly & Company | Compounds and methods for modulating FX-receptors |
| EA015632B9 (ru) * | 2006-05-24 | 2012-08-30 | Эли Лилли Энд Компани | Агонисты fxr |
| ES2340221T3 (es) | 2006-05-24 | 2010-05-31 | Eli Lilly And Company | Compuestos y procedimientos para modular fxr. |
-
2008
- 2008-07-03 TW TW097125064A patent/TW200906823A/zh unknown
- 2008-07-11 WO PCT/US2008/069719 patent/WO2009012125A1/en active Application Filing
- 2008-07-11 AU AU2008276236A patent/AU2008276236B2/en not_active Ceased
- 2008-07-11 US US12/600,879 patent/US8153624B2/en active Active
- 2008-07-11 EA EA201070148A patent/EA016475B1/ru not_active IP Right Cessation
- 2008-07-11 JP JP2010517082A patent/JP5373788B2/ja active Active
- 2008-07-11 RS RS20120099A patent/RS52216B/en unknown
- 2008-07-11 CA CA2693406A patent/CA2693406C/en not_active Expired - Fee Related
- 2008-07-11 PL PL08781651T patent/PL2178851T3/pl unknown
- 2008-07-11 DK DK08781651.8T patent/DK2178851T3/da active
- 2008-07-11 MX MX2010000502A patent/MX2010000502A/es active IP Right Grant
- 2008-07-11 ES ES08781651T patent/ES2376176T3/es active Active
- 2008-07-11 PE PE2008001168A patent/PE20090809A1/es not_active Application Discontinuation
- 2008-07-11 BR BRPI0814571-7A2A patent/BRPI0814571A2/pt not_active IP Right Cessation
- 2008-07-11 KR KR1020107000896A patent/KR101157334B1/ko not_active IP Right Cessation
- 2008-07-11 CN CN2008800247651A patent/CN101743232B/zh active Active
- 2008-07-11 AT AT08781651T patent/ATE539065T1/de active
- 2008-07-11 SI SI200830514T patent/SI2178851T1/sl unknown
- 2008-07-11 EP EP08781651A patent/EP2178851B1/en active Active
- 2008-07-11 PT PT08781651T patent/PT2178851E/pt unknown
- 2008-07-14 CL CL2008002051A patent/CL2008002051A1/es unknown
- 2008-07-14 AR ARP080103026A patent/AR067540A1/es not_active Application Discontinuation
-
2009
- 2009-11-19 IL IL202234A patent/IL202234A0/en unknown
-
2010
- 2010-01-12 DO DO2010000018A patent/DOP2010000018A/es unknown
- 2010-01-12 CO CO10002335A patent/CO6270212A2/es not_active Application Discontinuation
- 2010-01-15 SV SV2010003458A patent/SV2010003458A/es not_active Application Discontinuation
- 2010-01-15 TN TNP2010000028A patent/TN2010000028A1/fr unknown
- 2010-01-15 EC EC2010009879A patent/ECSP109879A/es unknown
- 2010-02-11 MA MA32615A patent/MA31683B1/fr unknown
-
2012
- 2012-01-16 HR HR20120048T patent/HRP20120048T1/hr unknown
- 2012-01-27 CY CY20121100098T patent/CY1112298T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1112298T1 (el) | Ενωσεις και μεθοδοι για ρυθμιση fxr | |
| EA200870570A1 (ru) | Агонисты fxr | |
| CY1121364T1 (el) | Νεοι κυτταροστατικοι νουκλεοζιτες 7-δεαζαπουρινης | |
| CY1118143T1 (el) | Ετεροκυκλικες ενωσεις χρησιμες ως αναστολεις της pdk1 | |
| CY1117776T1 (el) | Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες | |
| CY1116882T1 (el) | Ιμιδαζολοθειαδιαζολια προς χρηση ως αναστολεις πρωτεϊνικων κινασων | |
| CY1118129T1 (el) | 5-αλκυνυλ-πυριμιδινες | |
| CY1118362T1 (el) | Ανταγωνιστες υποδοχεων cgrp αζαϊνδανιου καρβοξαμιδιου πιπεριδινονης | |
| EA200870569A1 (ru) | Соединения и способы модуляции fxr | |
| CY1115836T1 (el) | Παραγωγα πυραζινονης και η χρηση τους στη θεραπευτικη αντιμετωπιση παθησεων των πνευμονων | |
| CY1117726T1 (el) | Θετικοι αλλοστερικοι ρυθμιστες υποδοχεα μ1 κινολιναμιδιου | |
| CY1110962T1 (el) | Τρικυκλικες ενωσεις και η χρηση τους ως διαμορφωτες του υποδοχεα γλυκοκορτικοειδων | |
| WO2007092751A3 (en) | Compounds and methods for modulating fx-receptors | |
| CY1115426T1 (el) | 1,3-δισυποκατεστημενα παραγωγα ιμιδαζολιδιν-2-ονης ως αναστολεις toy cyp 17 | |
| CY1112921T1 (el) | Ενεργοποιητες γλυκοκινασης πυρρολιδινονης | |
| CY1110115T1 (el) | Παραγωγα ακετυλενυλο-πυραζολο-πυριμιδινης ως mglur2 ανταγωνιστες | |
| EA201100447A1 (ru) | Органические соединения | |
| NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
| CY1113112T1 (el) | Παραγωγα θειενοπυριδονης ως ενεργοποιητες της πρωτεϊνικης κινασης (αμρκ) που ενεργοποιουνται απο το amρ | |
| EA201170832A1 (ru) | Пуриновые соединения | |
| CY1111351T1 (el) | Παραγωγα κινικλιδινης απο (ετερο) αρυλκυκλοεπτανοκαρβοξυλικο οξυ ως ανταγωνιστες μουσκαρινικου υποδοχεως | |
| CY1113102T1 (el) | Ενωσεις φαινυλπροπιοναμιδιου και η χρηση αυτων | |
| RS53617B1 (en) | NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | |
| CY1112311T1 (el) | Ενωσεις πυραζολινης ως ανταγωνιστες υποδοχεα αλατοκορτικοειδους | |
| ECSP066986A (es) | Beta-carbolinas utiles para tratar enfermedades inflamatorias |